Horizon Discovery Group has agreed to acquire GE Healthcare Dharmacon from parent General Electric for US$85 million to create a combined company which will focus on applying gene-editing and gene-modulation technologies in the life science field.
Colorado based Dharmacon is an indirect wholly owned subsidiary of General Electric that has grown into one of the leading providers of RNA interference products, with an extensive gene-editing product portfolio.
Horizon CFO Richard Vellacott said the acquisition “positions Horizon as a world leader in building, engineering, and modulating cells.”
Horizon disclosed that Dharmacon finished 2016 with net earnings of US$5.4 million on revenues of US$36.7 million, which is more than double Horizon’s own earnings last year (US$31.3 million).
The acquisition is still subject to approval by Horizon shareholders as well as regulator clearance in the US.
Full Content: GEN
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
DOJ and FTC Introduce Website for Reporting Anti-Competitive Healthcare Practices
Apr 18, 2024 by
CPI
US Congress Advances Legislation to Compel TikTok Sale
Apr 18, 2024 by
CPI
UK Financial Sector Advocates Enhanced Regulatory Accountability
Apr 18, 2024 by
CPI
Google and All 50 States Defend $700 Million Consumer Settlement
Apr 18, 2024 by
CPI
Colorado Enacts First Law to Protect Consumer Brainwave Data
Apr 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI